



(12) Translation of
European patent specification

(11) NO/EP 3784663 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 401/14 (2006.01)

C07D 417/14 (2006.01)

A61K 31/454 (2006.01)

C07D 491/08 (2006.01)

A61P 35/00 (2006.01)

C07D 491/10 (2006.01)

C07D 401/04 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2023.11.20
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.07.12
(86)	European Application Nr.	19726225.6
(86)	European Filing Date	2019.04.22
(87)	The European Application's Publication Date	2021.03.03
(30)	Priority	2018.04.23, US, 201862661525 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA
(72)	Inventor	ALEXANDER, Matthew, D., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA CARRANCIO, Soraya, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA CORREA, Matthew, D., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA GRANT, Virginia Heather, Sharron, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA HANSEN, Joshua, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA HARRIS, Roy, L., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA HUANG, Dehua, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA KERCHER, Timothy, S., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA LOPEZ-GIRONA, Antonia, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA NAGY, Mark, A., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA PLANTEVIN-KRENITSKY, Veronique, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR
TREATING LYMPHOMA**

(56) References
Cited: US-A1- 2011 196 150
 WO-A1-2008/033567

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

1. Forbindelse av formel (I):




n er 0, 1, 2, 3 eller 4.

*N(Cc1ccc(R)cc1Cc2c[nH]c3c2C(=O)N3C4CC(=O)NC(=O)C4)C5

(IX)

eller et farmasøytisk akseptabelt salt derav.


3. Forbindelsen ifølge krav 1 eller 2, hvori ring A er



5


hvori R^a er H, og R^b er C_{1-6} alkyl, ikke-aromatisk heterosyklyl, aryl, heteroaryl eller O-aryl; eller R^a og R^b sammen med karbonet som de er festet til danner et 3-6-leddet sykloalkyl, eller et 4-6-leddet ikke-aromatisk heterosyklyl; hvori alkylet, sykloalkylet, heterosyklylet, arylet eller heteroarylet eventuelt er substituert med ett eller flere halogener, C_{1-3} alkyl eller CN; eller

10



hvori R^c er H, halogen, OH eller (C_{1-3}) alkyl; og R^d er eventuelt substituert (C_{1-3}) alkyl, OR^1 , $C(O)N(R^2)_2$, $SO_2(C_{1-4})$ alkyl, C_{3-7} sykloalkyl, ikke-aromatisk heterosyklyl, aryl, heteroaryl eller O-heteroaryl; eller R^c og R^d sammen med karbonet som de er festet til danner et 3-6-leddet sykloalkyl, eller et 4-6-leddet ikke-aromatisk heterosyklyl; hvori R^1 er H, eventuelt substituert C_{1-6} alkyl, eller eventuelt substituert $-(C_{0-3})$ alkyl- (C_{3-7}) sykloalkyl; hver R^2 er uavhengig H, eller C_{1-6} alkyl; og hvori alkylet, sykloalkylet, heterosyklylet, arylet eller heteroarylet eventuelt er substituert med ett eller flere halogener, C_{1-3} alkyl eller CN; eller

15



hvori R^e er C_{1-6} alkyl, $SO_2(C_{1-4})$ alkyl, $-(C_{0-3})$ alkyl- (C_{3-7}) sykloalkyl, aryl, heteroaryl eller CO-aryl; hvori alkylet, sykloalkylet, arylet eller heteroarylet eventuelt er substituert.

20

4. Forbindelsen ifølge krav 1 eller 2, hvori ring A er et eventuelt substituert ikke-aromatisk heterosyklyl valgt fra azetidyl; piperidyl; piperazinyl; morfolinyl; 5-azaspiro[2,3]heksyl; 2-azaspiro[3.3]heptyl; 2-oksa-6-azaspiro[3.3]heptyl; 2-azaspiro[3.4]oktyl; 5-oksa-2-azaspiro[3.4]oktyl; 6-oksa-2-azaspiro[3.4]oktyl; 2-azaspiro[3.5]nonyl; 7-oksa-2-azaspiro[3.5]nonyl; oktahydrosyklopenta[c]pyrrolyl; 1,2,3,3a,4,6a-heksahydrosyklopenta[c]pyrrolyl; 6-azaspiro[3.4]oktyl; 2-oksa-6-azaspiro[3.4]oktyl; 6-azaspiro[2.5]oktyl; 7-azaspiro[3.5]nonyl; 1-oksa-8-azaspiro[4.5]dekanyl; 2-oksa-8-azaspiro[4.5]dekanyl; 2,8-diazaspiro[4.5]dekan-1-onyl; 3-oksa-9-azaspiro[5.5]undekanyl; 1,4-oksazepanyl; 8-azabisyklo[3.2.1]oktyl; og isoindolinyl.

30

5. Forbindelsen ifølge krav 4, hvori ring A er substitueret med én eller flere substituent uafhængig valgt fra halogen, C₁₋₆alkyl, OR¹, CON(R²)₂, SO₂(C₁₋₄alkyl), N(R²)SO₂(C₁₋₄alkyl), -(C₀₋₃alkyl)-(C₃₋₇sykloalkyl), (ikke-aromatisk heterosyklyl), aryl, heteroaryl, O-aryl, O-heteroaryl og C(O)aryl; hvori alkylet, sykloalkylet, heterosyklylet, arylet eller heteroarylet eventuelt er substitueret; hvori R¹ er H, eventuelt substitueret C₁₋₆alkyl, eller eventuelt substitueret -(C₀₋₃alkyl)-(C₃₋₇sykloalkyl); og hver R² er uafhængig H eller C₁₋₆alkyl; eller

hvor ring A er substitueret med én eller flere substituent uafhængig valgt fra F, Cl, Br, CH₃, CH₂CH₃, n-propyl, isopropyl, n-butyl, sek-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, CH₂F, CHF₂, CF₃, CH₂CH₂F, CH₂CHF₂, CH₂CF₃, CH(CH₃)CF₃, CH₂CH₂CF₃, OH, OCH₃, OCH₂CH₃, O-isopropyl, O-n-propyl, O-n-butyl, O-isobutyl, O-t-butyl, OCF₃, O-syklopropyl, O-syklobutyl, OCH₂-syklopropyl, OCH₂-syklobutyl, CONH₂, CONH(CH₃), CON(CH₃)₂, SO₂CH₃, SO₂CH₂CH₃, SO₂-isopropyl, syklopropyl, syklobutyl, CH₂-syklopropyl, CH₂-syklobutyl; (ikke-aromatisk heterosyklyl) valgt fra azetidyl, pyrrolidyl, pyrrolidonyl, isotiazolidyl, isotiazolidin-1,1-dioksy, piperidyl, piperazinyl, morfolinyl, 3-oksa-8-azabisyklo[3.2.1]oktyl eller 8-oksa-3-azabisyklo[3.2.1]oktyl, hvori heterosyklylet eventuelt er substitueret med én eller flere substituent uafhængig valgt fra CH₃, CH₂CH₃ eller CF₃, fenyl, O-fenyl eller C(O)-fenyl, hvori fenylet eventuelt er substitueret med én eller flere substituent uafhængig valgt fra F, Cl, CH₃, CN eller CONH₂; heteroaryl valgt fra pyrazolyl, imidazolyl, oksazolyl, isoksazolyl, oksadiazolyl, tiadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl eller benzoisoksazolyl, hvori heteroarylet eventuelt er substitueret med én eller flere substituent uafhængig valgt fra F, Cl, CF₃, CN, CONH₂, CONH(CH₃)₂ eller CON(CH₃)₂; O-pyridyl og O-pyrimidyl; eller

hvor ring A er substitueret med én eller flere substituent uafhængig valgt fra F, CH₃, CH₂CH₃, isopropyl, t-butyl, CH₂F, CF₃, CH(CH₃)CF₃, OH, OCH₃, OCH₂CH₃, O-isopropyl, O-n-propyl, O-isobutyl, O-t-butyl, OCF₃, O-syklobutyl, OCH₂-syklopropyl, CON(CH₃)₂, SO₂CH₂CH₃, SO₂-isopropyl, syklopropyl, syklobutyl, CH₂-syklopropyl; (ikke-aromatisk heterosyklyl) valgt fra pyrrolidyl, pyrrolidonyl, isotiazolidin-1,1-dioksidyl, morfolinyl, 3-oksa-8-azabisyklo[3.2.1]oktyl eller 8-oksa-3-azabisyklo[3.2.1]oktyl, hvori heterosyklylet eventuelt er substitueret med én eller flere CH₃, fenyl, O-fenyl eller C(O)-fenyl, hvori fenylet eventuelt er substitueret med én eller flere substituent uafhængig valgt fra F, Cl, CH₃, CN eller CONH₂; heteroaryl valgt fra pyrazolyl, oksazolyl, oksadiazolyl, tiadiazolyl, pyridyl, pyrazinyl, pyrimidyl eller benzoisoksazolyl, hvori heteroarylet eventuelt er substitueret med én eller flere substituent uafhængig valgt fra F, Cl, CF₃, CN, CONH₂, CON(CH₃)₂; O-pyridyl og O-pyrimidyl; eller

hvor ring A er azetidyl, substitueret med én eller flere substituent uafhængig valgt fra C₁₋₆alkyl, (ikke-aromatisk heterosyklyl), aryl, heteroaryl, O-aryl og O-

heteroaryl; hvori alkylet, sykloalkylet, heterosyklylet, arylet eller heteroarylet eventuelt er substituert; eller

hvor ring A er azetidyl, substituert med én eller flere substituent uavhengig valgt fra CH_2CH_3 , n-propyl, isopropyl, n-butyl, sek-butyl, isobutyl, t-butyl; CF_3 ; pyrrolidyl; pyrrolidonyl; piperidyl; piperazinyl; morfolinyl, eventuelt substituert med én eller flere CH_3 ; 3-oksa-8-azabisyklo[3.2.1]oktyl; 8-oksa-3-azabisyklo[3.2.1]oktyl; pyrazolyl; 2-pyridyl; 3-pyridyl; 4-pyridyl, fenyl; og O-fenyl; hvori fenylet eventuelt er substituert med én eller flere substituent uavhengig valgt fra F eller CN; eller

hvor ring A er piperidyl, substituert med én eller flere substituent uavhengig valgt fra halogen, C_{1-6} alkyl, OR^1 , $\text{CON}(\text{R}^2)_2$, $\text{SO}_2(\text{C}_{1-4}$ alkyl), C_{3-7} sykloalkyl, ikke-aromatisk heterosyklyl, aryl, heteroaryl og O-heteroaryl; hvori alkylet, sykloalkylet, heterosyklylet, arylet eller heteroarylet eventuelt er substituert; hvori R^1 er H, eventuelt substituert C_{1-6} alkyl, eller eventuelt substituert $-(\text{C}_{0-3}$ alkyl)-(C_{3-7} sykloalkyl); og hver R^2 er uavhengig H eller C_{1-6} alkyl; eller

hvor ring A er piperidyl, substituert med én eller flere substituent uavhengig valgt fra F, Cl, CH_3 , CH_2CH_3 , n-propyl, isopropyl, n-butyl, sek-butyl, isobutyl, t-butyl, CH_2F , CHF_2 , CF_3 , OH, OCH_3 , OCH_2CH_3 , O-n-propyl, O-isopropyl, O-n-butyl, O-isobutyl, O-t-butyl, OCF_3 , O-syklopropyl, O-syklobutyl, OCH_2 -syklopropyl, OCH_2 -syklobutyl, CONH_2 , $\text{CONH}(\text{CH}_3)$, $\text{CON}(\text{CH}_3)_2$, SO_2CH_3 , $\text{SO}_2\text{CH}_2\text{CH}_3$, SO_2 -isopropyl, syklopropyl, syklobutyl, pyrrolidonyl, isotiazolidin-1,1-dioksidyl, morfolinyl; tetrahydrofuranlyl, tetrahydropyranlyl, pyrazolyl; oksadiazolyl, eventuelt substituert med CH_3 ; fenyl, eventuelt substituert med én eller flere F; 2-pyridyl, 3-pyridyl, 4-pyridyl, O-2-pyridyl, O-3-pyridyl og O-4-pyridyl; eller

hvor ring A er piperidyl, substituert med én eller flere substituent uavhengig valgt fra F, CH_3 , CH_2CH_3 , isopropyl, t-butyl, CHF_2 , CF_3 , OH, OCH_3 , OCH_2CH_3 , O-isopropyl, O-isobutyl, O-t-butyl, OCF_3 , O-syklobutyl, OCH_2 -syklopropyl, $\text{CON}(\text{CH}_3)_2$, $\text{SO}_2\text{CH}_2\text{CH}_3$, SO_2 -isopropyl, syklopropyl, pyrrolidonyl, isotiazolidin-1,1-dioksidyl, morfolinyl; tetrahydropyranlyl, pyrazolyl, oksadiazolyl, substituert med CH_3 ; fenyl, eventuelt substituert med én eller flere F; 2-pyridyl og O-2-pyridyl; eller

hvor ring A er piperazinyl, substituert med én eller flere substituent uavhengig valgt fra C_{1-6} alkyl, $\text{SO}_2(\text{C}_{1-4}$ alkyl), $-(\text{C}_{0-3}$ alkyl)-(C_{3-7} sykloalkyl), aryl, heteroaryl og CO-aryl; hvori alkylet, sykloalkylet, arylet eller heteroarylet eventuelt er substituert; eller

hvor ring A er piperazinyl, substituert med én eller flere substituent uavhengig valgt fra CH_3 , CH_2CH_3 , n-propyl, isopropyl, n-butyl, sek-butyl, isobutyl, t-butyl, CF_3 , CH_2CF_3 , $\text{CH}(\text{CH}_3)\text{CF}_3$, SO_2CH_3 , $\text{SO}_2\text{CH}_2\text{CH}_3$, SO_2 -isopropyl, syklopropyl, syklobutyl, (CH_2) syklopropyl, (CH_2) syklobutyl, fenyl, eventuelt substituert med én eller flere

Cl, F, CN, CH₃, CONH₂; pyrazolyl, eventuelt substituert med CH₃ eller CH₂CH₃; oksazolyl, eventuelt substituert med CH₃ eller CH₂CH₃; oksadiazolyl, eventuelt substituert med CH₃ eller CH₂CH₃; tiadiazolyl, eventuelt substituert med CH₃, CH₂CH₃, eller CF₃; 2-pyridyl, 3-pyridyl eller 4-pyridyl, hver eventuelt substituert med Cl, F, CF₃, CN, CONH₂, CONH(CH₃) eller CON(CH₃)₂; pyrazinyl, eventuelt substituert med CH₃ eller CH₂CH₃; pyrimidyl, eventuelt substituert med OCH₃; benzoisoksazolyl; og CO(fenyl), hvori fenylet eventuelt er fluorert; eller hvori ring A er piperazinyl, substituert med én eller flere substituenten uavhengig valgt fra CH₃, isopropyl, t-butyl, CH(CH₃)CF₃, SO₂CH₂CH₃, SO₂-isopropyl, syklopropyl, syklobutyl, (CH₂)syklopropyl, fenyl, eventuelt substituert med én eller flere Cl, F, CN, CH₃, CONH₂; pyrazolyl, eventuelt substituert med CH₃; oksazolyl, eventuelt substituert med CH₃; oksadiazolyl, eventuelt substituert med CH₂CH₃; tiadiazolyl, eventuelt substituert med CH₃ eller CH₂CH₃; 2-pyridyl, eventuelt substituert med Cl, F, CF₃, CN eller CONH₂; 3-pyridyl, eventuelt substituert med CF₃, CN, CONH₂ eller CON(CH₃)₂; 4-pyridyl, eventuelt substituert med CONH₂; pyrazinyl, eventuelt substituert med CH₃; pyrimidyl, eventuelt substituert med OCH₃; benzoisoksazolyl; og CO(fenyl), hvori fenylet eventuelt er fluorert; eller hvori ring A er morfolinyl, og R er F eller CH₃, og n er 1; eller hvori ring A er valgt fra 5-azaspiro[2,3]heksyl; 2-azaspiro[3.3]heptyl; 2-oksa-6-azaspiro[3.3]heptyl; 2-azaspiro[3.4]oktyl; 5-oksa-2-azaspiro[3.4]oktyl; 6-oksa-2-azaspiro[3.4]oktyl; 2-azaspiro[3.5]nonyl; 7-oksa-2-azaspiro[3.5]nonyl; oktahydrosyklopenta[c]pyrrolyl; 1,2,3,3a,4,6a-heksahydrosyklopenta[c]pyrrolyl; 6-azaspiro[3.4]oktyl; 2-oksa-6-azaspiro[3.4]oktyl; 6-azaspiro[2.5]oktyl; 7-azaspiro[3.5]nonyl; 1-oksa-8-azaspiro[4.5]dekanyl; 2-oksa-8-azaspiro[4.5]dekanyl; 2,8-diazaspiro[4.5]dekan-1-nonyl; 3-oksa-9-azaspiro[5.5]undekanyl; 1,4-oksazepanyl; 8-azabisyklo[3.2.1]oktyl; og isoindolinyl; hver eventuelt substituert med én eller flere CH₃ eller F.


6. Forbindelsen ifølge et hvilket som helst av kravene 1–5, hvori R er F.

30


7. Forbindelsen ifølge et hvilket som helst av kravene 1–5, hvori R er CH₃.

8. Forbindelsen ifølge et hvilket som helst av kravene 1–7, hvori n er 1.


35 9. Forbindelse ifølge krav 1, hvori forbindelsen er (Compound = forbindelse)




Compound 1,




Compound 2,




Compound 3,




Compound 4,




Compound 5,




Compound 6,




Compound 7,




Compound 8,




Compound 9,




Compound 10,




Compound 11,




Compound 12,




Compound 13,




Compound 14,




Compound 15,




Compound 16,




Compound 17,




Compound 18,




Compound 19,




Compound 20,




Compound 21,




Compound 22,




Compound 23,




Compound 24,




Compound 25,




Compound 26,




Compound 27,




Compound 28,




Compound 29,




Compound 30,




Compound 31,




Compound 32,




Compound 33,




Compound 34,




Compound 35,




Compound 36,




Compound 37,




Compound 38,




Compound 39,




Compound 40,




Compound 41,




Compound 42,




Compound 43,




Compound 44,




Compound 45,




Compound 46,




Compound 47,




Compound 48,




Compound 49,




Compound 50,




Compound 51,




Compound 52,




Compound 53,




Compound 54,




Compound 55,




Compound 56,




Compound 57,




Compound 58,




Compound 59,




Compound 60,




Compound 61,




Compound 62,




Compound 63,




Compound 64,




Compound 65,




Compound 66,




Compound 67,




Compound 68,




Compound 69,




Compound 70,




Compound 71,




Compound 72,




Compound 73,




Compound 74,




Compound 75,




Compound 76,




Compound 77,




Compound 78,




Compound 79,




Compound 80,




Compound 81,




Compound 82,




Compound 83,




Compound 84,


















Compound 85,






Compound 86,




Compound 87,




5







Compound 106,




Compound 107,




Compound 108,




Compound 109,




Compound 110,




Compound 111,




Compound 112,




Compound 113,




Compound 114,




Compound 115,




Compound 116,




Compound 117,




Compound 118,




Compound 119,




Compound 120,




Compound 121,




Compound 122,




Compound 123,




Compound 124,




Compound 125,




Compound 126,




Compound 127,




Compound 128,




Compound 129,




Compound 130,




Compound 131,




Compound 132,




Compound 133,




Compound 134,




Compound 135,




Compound 136,




Compound 137,




Compound 138,




Compound 139,




Compound 140,




Compound 141,




Compound 142,




Compound 143,




Compound 144,




Compound 145,




Compound 146,




Compound 147,




Compound 148,




Compound 149,




Compound 150,




Compound 151,




Compound 152,




Compound 153,




Compound 154,




Compound 155,




Compound 156,




Compound 157,




Compound 158,




Compound 159,




Compound 160,




Compound 161,




Compound 162,




Compound 163,




Compound 164,




Compound 165,




Compound 166,




Compound 167,




Compound 168,




Compound 169,




Compound 170,




Compound 171,




Compound 172,




Compound 173,




Compound 174,




Compound 175,




Compound 176,




Compound 177,




Compound 178,




Compound 179,




Compound 180,




Compound 181,




Compound 182,




Compound 183,




Compound 184,




Compound 185,




Compound 186,




Compound 187,




Compound 188,




Compound 189,




Compound 190,




Compound 191,




Compound 192,




Compound 193,




Compound 194,




Compound 195,




Compound 196,




Compound 197,




Compound 198,




Compound 199,




Compound 200,




Compound 201,




Compound 202,




Compound 203,




Compound 204,




Compound 205,




Compound 206,




Compound 207,




Compound 208,




Compound 209,




Compound 210,




Compound 211,




Compound 212,




Compound 213,




Compound 214,




Compound 215,




Compound 216,




Compound 217,




Compound 218,




Compound 219,




Compound 220,




Compound 221,




Compound 222,




Compound 223,




Compound 224,




Compound 225,




Compound 226,




Compound 227,




Compound 228,




Compound 229,




Compound 230,




Compound 231,




Compound 232,




Compound 233,




Compound 234,




Compound 235,




Compound 236,




Compound 237,




Compound 238,




Compound 239,




Compound 240,




Compound 241,




Compound 242,




Compound 243,




Compound 244,




Compound 245,




Compound 246,



Compound 247,



Compound 248, eller




Compound 249,

5

eller et farmasøytisk akseptabelt salt derav.

10. Forbindelsen ifølge krav 1, hvori forbindelsen er



10

eller et farmasøytisk akseptabelt salt derav.

11. Farmasøytisk sammensetning omfattende en effektiv mengde av en forbindelse ifølge et hvilket som helst av kravene 1–10, eller et farmasøytisk akseptabelt salt, tautomer, isotopolog eller stereoisomer derav, og en farmasøytisk akseptabel bærer, eksipiens eller
5 vehikkel.
12. Forbindelse ifølge et hvilket som helst av kravene 1–10, eller en farmasøytisk sammensetning ifølge krav 11 for anvendelse i en fremgangsmåte for behandling av diffust storcellet B-cellelymfom (DLBCL), fremgangsmåten omfattende administrering til et
10 individ med behov derav av en effektiv mengde av forbindelsen eller den farmasøytiske sammensetningen.
13. Forbindelsen eller den farmasøytiske sammensetningen for anvendelse ifølge krav 12, hvori DLBCL er residiverende eller refraktær DLBCL.
15
14. Forbindelsen eller den farmasøytiske sammensetningen for anvendelse ifølge krav 13, hvori DLBCL er refraktær ovenfor én eller flere av rituksimab, syklofosfamid, doksorubicin, vinkristin, prednison, etoposid, bendamustin, lenalidomid eller gemcitabin.
- 20 15. Forbindelsen eller den farmasøytiske sammensetningen for anvendelse ifølge krav 12, hvori DLBCL er nylig diagnostisert DLBCL.
- 25 16. Forbindelsen eller den farmasøytiske sammensetningen for anvendelse ifølge et hvilket som helst av kravene 12–15, videre omfattende administrering av én eller flere av rituksimab, syklofosfamid, doksorubicin, vinkristin, prednison, etoposid, bendamustin, lenalidomid eller gemcitabin.